Cargando…
Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion
TP53 (p53) is a pivotal player in tumor suppression with fifty percent of all invasive tumors displaying mutations in the TP53 gene. In the present study, we characterized colon cancer cells (HCT116 p53 (−/−)) with TP53 deletion, a sub-line derived from HCT116-p53 (+/+) cells. RNA sequencing and net...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904745/ https://www.ncbi.nlm.nih.gov/pubmed/33515271 http://dx.doi.org/10.1007/s00204-021-02979-4 |
_version_ | 1783654978294906880 |
---|---|
author | Kadioglu, Onat Saeed, Mohamed Mahmoud, Nuha Azawi, Shaymaa Mrasek, Kristin Liehr, Thomas Efferth, Thomas |
author_facet | Kadioglu, Onat Saeed, Mohamed Mahmoud, Nuha Azawi, Shaymaa Mrasek, Kristin Liehr, Thomas Efferth, Thomas |
author_sort | Kadioglu, Onat |
collection | PubMed |
description | TP53 (p53) is a pivotal player in tumor suppression with fifty percent of all invasive tumors displaying mutations in the TP53 gene. In the present study, we characterized colon cancer cells (HCT116 p53 (−/−)) with TP53 deletion, a sub-line derived from HCT116-p53 (+/+) cells. RNA sequencing and network analyses were performed to identify novel drug resistance mechanisms. Chromosomal aberrations were identified by multicolor fluorescence in situ hybridization (mFISH) and array comparative genomic hybridization (aCGH). Numerous genes were overexpressed in HCT116 p53 (−/−) cells: RND3/RhoE (235.6-fold up-regulated), DCLK1 (60.2-fold up-regulated), LBH (31.9-fold up-regulated), MYB (28.9-fold up-regulated), TACSTD2 (110.1-fold down-regulated), NRIP1 (81.5-fold down-regulated) and HLA-DMB (69.7-fold down-regulated) are among the identified genes with potential influence on multidrug resistance (MDR) and they are associated with cancer progression and tumorigenesis, according to previously published studies. Probably due to TP53 deletion, disturbances in DNA repair and apoptosis are leading to aberrancies in cellular and organismal organization, ultimately increasing tumorigenesis and cancer progression potential. With NFκB, PI3K and HSP70, being at the center of merged protein network, and TH1-2 pathways, being among the influenced pathways, it can be speculated that the inflammatory pathway contributes to a resistance phenotype together with cell cycle regulation and heat-shock response. HCT116-p53 (−/−) cells have more chromosomal aberrations, gains and losses in copy numbers than HCT116-p53 (+/+) cells. In conclusion, numerous genomic aberrations, which might be associated with yet unknown drug resistance mechanisms, were identified. This may have important implications for future treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-021-02979-4. |
format | Online Article Text |
id | pubmed-7904745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-79047452021-03-09 Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion Kadioglu, Onat Saeed, Mohamed Mahmoud, Nuha Azawi, Shaymaa Mrasek, Kristin Liehr, Thomas Efferth, Thomas Arch Toxicol Molecular Toxicology TP53 (p53) is a pivotal player in tumor suppression with fifty percent of all invasive tumors displaying mutations in the TP53 gene. In the present study, we characterized colon cancer cells (HCT116 p53 (−/−)) with TP53 deletion, a sub-line derived from HCT116-p53 (+/+) cells. RNA sequencing and network analyses were performed to identify novel drug resistance mechanisms. Chromosomal aberrations were identified by multicolor fluorescence in situ hybridization (mFISH) and array comparative genomic hybridization (aCGH). Numerous genes were overexpressed in HCT116 p53 (−/−) cells: RND3/RhoE (235.6-fold up-regulated), DCLK1 (60.2-fold up-regulated), LBH (31.9-fold up-regulated), MYB (28.9-fold up-regulated), TACSTD2 (110.1-fold down-regulated), NRIP1 (81.5-fold down-regulated) and HLA-DMB (69.7-fold down-regulated) are among the identified genes with potential influence on multidrug resistance (MDR) and they are associated with cancer progression and tumorigenesis, according to previously published studies. Probably due to TP53 deletion, disturbances in DNA repair and apoptosis are leading to aberrancies in cellular and organismal organization, ultimately increasing tumorigenesis and cancer progression potential. With NFκB, PI3K and HSP70, being at the center of merged protein network, and TH1-2 pathways, being among the influenced pathways, it can be speculated that the inflammatory pathway contributes to a resistance phenotype together with cell cycle regulation and heat-shock response. HCT116-p53 (−/−) cells have more chromosomal aberrations, gains and losses in copy numbers than HCT116-p53 (+/+) cells. In conclusion, numerous genomic aberrations, which might be associated with yet unknown drug resistance mechanisms, were identified. This may have important implications for future treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-021-02979-4. Springer Berlin Heidelberg 2021-01-30 2021 /pmc/articles/PMC7904745/ /pubmed/33515271 http://dx.doi.org/10.1007/s00204-021-02979-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Toxicology Kadioglu, Onat Saeed, Mohamed Mahmoud, Nuha Azawi, Shaymaa Mrasek, Kristin Liehr, Thomas Efferth, Thomas Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
title | Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
title_full | Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
title_fullStr | Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
title_full_unstemmed | Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
title_short | Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
title_sort | identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion |
topic | Molecular Toxicology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904745/ https://www.ncbi.nlm.nih.gov/pubmed/33515271 http://dx.doi.org/10.1007/s00204-021-02979-4 |
work_keys_str_mv | AT kadiogluonat identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion AT saeedmohamed identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion AT mahmoudnuha identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion AT azawishaymaa identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion AT mrasekkristin identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion AT liehrthomas identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion AT efferththomas identificationofpotentialnoveldrugresistancemechanismsbygenomicandtranscriptomicprofilingofcoloncancercellswithp53deletion |